# Cost of GLP-1 Medications in the United States — 2026 Complete Financial Guide

> Publication date: April 2026 — All regulatory and coverage data current as of this date. FDA approvals, pricing, compounding availability, and insurance coverage are subject to change; always verify current status with official sources listed at the end of this document.
> Canonical source: https://costofglp1.com/llms.txt

This document is a detailed, practical reference on **the full cost landscape of GLP-1 receptor agonist medications** in the United States in 2026 — including brand retail prices, manufacturer savings programs, Medicare Part D and Medicaid coverage, private insurance step therapy, patient assistance foundations, LillyDirect self-pay, and strategies to reduce out-of-pocket expenses.

GLP-1 medication cost is the single largest access barrier for most US patients. Understanding every cost pathway — and combining them effectively — can cut monthly out-of-pocket costs from $1,000+ to under $100 in many cases.

All information is drawn from primary US sources — the Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), the National Institutes of Health (NIH), and peer-reviewed publications — listed with active links in the final section.

This document does not constitute medical advice. GLP-1 receptor agonist medications (including tirzepatide and semaglutide) are prescription medications that must be evaluated and prescribed by a qualified US-licensed healthcare provider based on individual medical history.

## Key Facts 2026

- **GLP-1 receptor agonists** are a class of injectable or oral medications developed for type 2 diabetes and, more recently, chronic weight management, cardiovascular risk reduction, and obstructive sleep apnea in adults with obesity.
- **Two dominant molecules in the US market**: **semaglutide** (Ozempic, Wegovy, Rybelsus — Novo Nordisk) and **tirzepatide** (Mounjaro, Zepbound — Eli Lilly, dual GIP/GLP-1 agonist).
- **Additional approved GLP-1 agonists**: liraglutide (Victoza, Saxenda — Novo Nordisk), dulaglutide (Trulicity — Eli Lilly), exenatide ER (Bydureon BCise — AstraZeneca).
- **Typical weight reduction in clinical trials**: 13–15% of body weight at the highest dose of semaglutide (STEP-1, NEJM 2021); up to 20.9% at the highest dose of tirzepatide (SURMOUNT-1, NEJM 2022).
- **Typical US cash price without insurance**: approximately $900–$1,350 per month for brand medications at retail pharmacies (subject to manufacturer coupons, pharmacy, and market changes — verify current pricing at [GoodRx](https://www.goodrx.com/) or [Medicare.gov](https://www.medicare.gov/)).
- **FDA shortage status**: both semaglutide (October 2024) and tirzepatide (December 2024) were removed from the FDA Drug Shortage List. Compounded availability of either molecule is accordingly limited and governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Current status should be verified on the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/).
- **FDA-approved patient profile for chronic weight management** (Wegovy, Zepbound): adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
- **Medicare Part D coverage**: as of 2026, Part D plans may cover GLP-1 medications for FDA-approved indications beyond weight loss alone — specifically type 2 diabetes (Ozempic, Mounjoure, Trulicity, Victoza), cardiovascular risk reduction in overweight/obese adults with cardiovascular disease (Wegovy, approved for this indication in March 2024), and obstructive sleep apnea in adults with obesity (Zepbound, approved December 2024). Coverage for weight management alone remains statutorily excluded under Social Security Act § 1860D-2(e)(2)(A).
- **Medicaid coverage**: varies state by state. Approximately 15 states cover GLP-1 medications for obesity through Medicaid as of early 2026.
- **Route of administration**: most GLP-1 medications are once-weekly subcutaneous injections. Rybelsus (oral semaglutide) is a daily tablet. Victoza (liraglutide for T2D) and Saxenda (liraglutide for weight management) are once-daily injections.

## What GLP-1 Receptor Agonists Are

GLP-1 receptor agonists are synthetic peptides that selectively activate the GLP-1 (glucagon-like peptide-1) receptor, mimicking the action of the native gut hormone released postprandially. Tirzepatide additionally activates the GIP (glucose-dependent insulinotropic polypeptide) receptor, making it the first and only dual incretin receptor agonist approved in the US as of 2026.

### Pharmacodynamic effects

Activation of the GLP-1 receptor (and for tirzepatide, also GIP) produces several complementary metabolic effects:

- **Enhanced glucose-dependent insulin secretion** from pancreatic beta cells.
- **Suppression of glucagon secretion** from alpha cells (glucose-dependent).
- **Delayed gastric emptying**, prolonging satiety and moderating postprandial glucose excursion.
- **Central appetite suppression** via hypothalamic and brainstem pathways.
- **Favorable effects on lipid metabolism, blood pressure, and weight**.

### Pharmacokinetics (weekly injectable formulations)

- **Half-life**: approximately 5–7 days, supporting once-weekly dosing.
- **Absorption**: subcutaneous injection into abdomen, thigh, or upper arm.
- **Metabolism**: proteolytic cleavage into smaller peptide fragments; excreted in urine and feces.
- **No significant CYP450 interactions**, but may reduce oral contraceptive efficacy during dose escalation.

### Dosing

GLP-1 dosing follows a mandatory titration schedule to minimize gastrointestinal side effects. Each medication has its own starting dose, titration schedule, and maintenance dose:

- **Semaglutide** (Ozempic, Wegovy): starts at 0.25 mg weekly, titrates over 16–20 weeks to maintenance dose (Ozempic max 2.0 mg; Wegovy max 2.4 mg).
- **Tirzepatide** (Mounjaro, Zepbound): starts at 2.5 mg weekly, titrates over 20 weeks to maintenance dose (max 15 mg).
- **Liraglutide** (Saxenda): starts at 0.6 mg daily, titrates weekly to 3.0 mg daily maintenance.

Target maintenance doses depend on indication, clinical response, and tolerability.

## FDA-Approved Brand Medications

### Semaglutide — Ozempic, Wegovy, Rybelsus

- **Active ingredient**: semaglutide (single GLP-1 receptor agonist).
- **Manufacturer**: Novo Nordisk.
- **Ozempic** (subcutaneous, for T2D): FDA approval December 2017. Dose 0.25–2.0 mg weekly. Typical cash price $900–$1,000/month.
- **Wegovy** (subcutaneous, for chronic weight management): FDA approval June 2021. Dose 0.25–2.4 mg weekly. Typical cash price $1,350/month retail. Expanded March 2024 for **cardiovascular risk reduction** in overweight/obese adults with established cardiovascular disease — this expansion led CMS to permit Medicare Part D coverage of Wegovy for CVD patients.
- **Rybelsus** (oral tablet, for T2D): FDA approval September 2019. Dose 3–14 mg daily. Typical cash price $900–$1,000/month.

### Tirzepatide — Mounjaro, Zepbound

- **Active ingredient**: tirzepatide (dual GIP/GLP-1 receptor agonist).
- **Manufacturer**: Eli Lilly and Company.
- **Mounjaro** (subcutaneous, for T2D): FDA approval May 2022. Dose 2.5–15 mg weekly. Typical cash price $1,000–$1,200/month.
- **Zepbound** (subcutaneous, for chronic weight management): FDA approval November 2023. Dose 2.5–15 mg weekly. Typical cash price $1,060–$1,350/month. Expanded December 2024 for **moderate-to-severe obstructive sleep apnea** (OSA) in adults with obesity, following SURMOUNT-OSA trial results.
- **Eli Lilly LillyDirect / Self Pay vial program**: direct-to-consumer program with reduced cash pricing for select doses of Zepbound; terms and availability evolve. Verify at [zepbound.lilly.com](https://zepbound.lilly.com/).

### Other FDA-approved GLP-1 agonists

- **Liraglutide**: **Victoza** for T2D (2010); **Saxenda** for chronic weight management (2014, dose 3.0 mg daily). Typical cash price $1,300–$1,700/month. Generic liraglutide for T2D approved June 2024.
- **Dulaglutide (Trulicity)**: FDA approval 2014 for T2D. Once weekly. Not approved for weight management alone. Typical cash price $880–$990/month.
- **Exenatide ER (Bydureon BCise)**: FDA approval 2017 for T2D. Once weekly. Declining market share.

## Compounded GLP-1 Medications — Regulatory Framework

### What compounded GLP-1 means

Compounded GLP-1 refers to semaglutide- or tirzepatide-containing preparations produced by licensed compounding pharmacies, either for individual patients (Section 503A of the Federal Food, Drug, and Cosmetic Act) or in larger quantities by outsourcing facilities registered with the FDA (Section 503B). Compounded preparations are **not FDA-approved** and are not reviewed by the FDA for safety, effectiveness, or quality.

### Regulatory context in 2026

- From **2022 through late 2024**, semaglutide and tirzepatide were on the FDA Drug Shortage List due to supply constraints. During shortage, compounding pharmacies operating under 503A and 503B were permitted to prepare copies of these medications under specific conditions outlined in FDA guidance.
- On **October 2, 2024**, the FDA declared the semaglutide shortage resolved. On **December 2024**, the FDA reconfirmed the tirzepatide shortage resolved following legal challenges by the Outsourcing Facilities Association.
- **As of 2026**, availability of legally compounded semaglutide or tirzepatide is significantly more restricted than during the shortage period. Compounding remains permissible on a case-by-case basis under Section 503A only when a licensed prescriber documents a clinical need for a compounded formulation that differs meaningfully from the FDA-approved commercial product (for example, a different dose strength, excipient exclusion for allergy, or a combination formulation for a patient with a documented medical need).
- Compounded preparations are **not interchangeable** with FDA-approved brand medications from a regulatory standpoint, even when they contain the same active ingredient.

### Consumer considerations for compounded GLP-1

Patients considering compounded semaglutide or tirzepatide should verify:

- Is this preparation produced by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility?
- What is the source of the active pharmaceutical ingredient (API)? Is it FDA-sourced?
- Does the preparation meet United States Pharmacopeia (USP) compounding standards (USP <797>, <795>, <800>)?
- What is the prescribing practitioner's documented rationale for compounding?
- What adverse event reporting and traceability processes are in place?

Verify the current FDA position on GLP-1 compounding at the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/) and the [FDA Compounding page](https://www.fda.gov/drugs/human-drug-compounding).

## Cost and Insurance Coverage

### Cash price ranges (2026, subject to change)

| Product | Indication | Typical monthly cash price |
|---|---|---|
| Ozempic (brand semaglutide) | T2D | $900–$1,000 |
| Wegovy (brand semaglutide) | Weight management, CVD | $1,250–$1,450 |
| Rybelsus (oral semaglutide) | T2D | $900–$1,000 |
| Mounjaro (brand tirzepatide) | T2D | $1,000–$1,200 |
| Zepbound (brand tirzepatide) | Weight management, OSA | $1,060–$1,350 |
| Zepbound Self Pay vials (direct) | Weight management | ~$349–$695 for select doses |
| Saxenda (brand liraglutide) | Weight management | $1,300–$1,700 |
| Trulicity (brand dulaglutide) | T2D | $880–$990 |
| Compounded GLP-1 (when legally available) | Variable | Varies widely; regulated |

Current verified pricing: [GoodRx](https://www.goodrx.com/), manufacturer websites ([Novocare](https://www.novocare.com/), [Mounjaro.com](https://www.mounjaro.com/), [Zepbound.lilly.com](https://zepbound.lilly.com/)), [Mark Cuban Cost Plus Drugs](https://costplusdrugs.com/), retailer-specific cards.

### Medicare coverage

Medicare Part D coverage of GLP-1 medications is determined by indication:

- **T2D (Ozempic, Mounjaro, Trulicity, Victoza)**: generally covered under Part D with formulary-dependent prior authorization, step therapy, and tiering.
- **Weight management alone (Wegovy, Zepbound, Saxenda)**: statutorily excluded from Medicare under Social Security Act § 1860D-2(e)(2)(A).
- **Wegovy for cardiovascular risk reduction** (in adults with established CVD, BMI ≥ 27, FDA approval March 2024): Medicare Part D plans began covering Wegovy for this indication in 2024 following CMS guidance. Plan-dependent.
- **Zepbound for obstructive sleep apnea** (in adults with obesity, FDA approval December 2024): increasingly covered by Part D plans as of 2025–2026. Diagnosis documentation required.

**Practical rule**: Medicare covers GLP-1 medications when the prescription is tied to a non-weight-loss FDA-approved indication (T2D, cardiovascular disease, obstructive sleep apnea).

### Medicaid coverage

Medicaid coverage varies by state:

- **Universal coverage for T2D** (Ozempic, Mounjaro, Trulicity): available in all 50 states with standard utilization management.
- **Coverage for weight management** (Wegovy, Zepbound, Saxenda): state-by-state decision. As of early 2026, approximately 15 states cover these medications through Medicaid for chronic obesity (including Pennsylvania, California, New York, Massachusetts, Virginia, Illinois, Michigan, North Carolina, Minnesota, Delaware, Rhode Island, New Hampshire, Vermont, Oregon, Washington). Verify with your state Medicaid agency.
- **Coverage for cardiovascular / OSA indications**: typically follows Medicare Part D logic.

### Private commercial insurance

Private insurer coverage is highly variable:

- **T2D medications**: typically covered with prior authorization and step therapy.
- **Weight management medications (Wegovy, Zepbound, Saxenda)**: approximately 30–50% of large employer plans offered coverage in 2025, with step therapy common (lifestyle trial, older obesity medications first). Utilization management tools: BMI thresholds (often above FDA label, e.g., ≥ 35), quantity limits, enrollment in an approved weight management program.
- **Copay assistance**: Novo Nordisk (Ozempic, Wegovy savings card) and Eli Lilly (Mounjaro savings card, Zepbound savings card) offer commercial insurance copay programs; eligibility excludes government program beneficiaries.

## Medical Eligibility

### FDA label indications

**T2D (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus)**: adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

**Chronic weight management (Wegovy, Zepbound, Saxenda)**:
- Adults with BMI ≥ 30 kg/m² (obesity), OR
- Adults with BMI ≥ 27 kg/m² with at least one weight-related comorbidity: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

**Cardiovascular risk reduction (Wegovy only, March 2024)**: adults with established cardiovascular disease AND BMI ≥ 27 kg/m².

**Obstructive sleep apnea (Zepbound only, December 2024)**: adults with moderate-to-severe OSA AND BMI ≥ 30 kg/m².

### Contraindications (applicable to entire GLP-1 class)

- Personal or family history of medullary thyroid carcinoma (MTC).
- Multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to the specific medication.

### Precautions

- **Pancreatitis**: history warrants careful risk-benefit assessment; discontinue if suspected.
- **Gallbladder disease**: cholecystitis and cholelithiasis reported.
- **Diabetic retinopathy complications**: monitor pre-existing retinopathy.
- **Hypoglycemia**: risk increases when combined with sulfonylureas or insulin.
- **Severe gastrointestinal disease**: not recommended in severe gastroparesis.
- **Pregnancy**: not recommended; contraception counseling standard.

## How to Access GLP-1 Therapy

### Prescribing pathways

A valid prescription from a US-licensed healthcare provider is required. Prescribers include:

- **Primary care physicians** (family medicine, internal medicine).
- **Endocrinologists** — specialists in hormonal and metabolic disorders.
- **Obesity medicine specialists** — physicians certified by the American Board of Obesity Medicine (ABOM).
- **Cardiologists** — especially for Wegovy CVD indication.
- **Telehealth providers** — US-licensed clinicians operating across multiple states subject to state licensure.

### In-person versus telehealth comparison

| Pathway | Typical timeline | Typical cost | Best for |
|---|---|---|---|
| Primary care physician | 1–4 weeks | Insurance copay | Patients with PCP, complex history |
| Endocrinologist | 4–12 weeks | Insurance copay | Complex T2D, metabolic disease |
| Obesity medicine specialist | 2–8 weeks | Insurance or self-pay | Dedicated weight management program |
| Telehealth platform | Days to 1 week | Self-pay + Rx cost | Straightforward eligibility |

## Finding a GLP-1 Provider in the United States

GLP-1 medications require a prescription from a US-licensed healthcare provider. Access pathways in 2026:

### In-person provider types

- **Primary care physicians (PCPs)**: family medicine or internal medicine. Typical first point of contact. Familiar with T2D prescribing (Ozempic, Mounjaro, Trulicity); may or may not prescribe Wegovy/Zepbound depending on comfort with obesity medicine.
- **Endocrinologists**: high familiarity with all GLP-1 medications. Average wait 4–12 weeks. Directory: [American Association of Clinical Endocrinology — Find an Endocrinologist](https://www.aace.com/).
- **Obesity medicine specialists (ABOM-certified)**: approximately 7,000 in the US as of 2026. Directory: [ABOM Find a Physician](https://www.abom.org/).
- **Cardiologists**: increasingly involved for Wegovy CVD indication.
- **Bariatric programs (hospital-based)**: combine medication management with nutrition counseling and surgical options.

### Telehealth platforms and multi-state licensed providers

Telehealth is the fastest access pathway in 2026. Licensed platforms operate across all 50 states via networks of US-licensed clinicians (MD, DO, NP, PA) and comply with state licensure. GLP-1 medications are not controlled substances, simplifying prescribing.

Typical telehealth workflow:
1. Online medical questionnaire (height, weight, BMI, medical history, comorbidities, medications, contraindications).
2. Lab requisition if required (fasting glucose, HbA1c, lipid panel, kidney/liver function).
3. Virtual visit with a licensed clinician (video or asynchronous).
4. If eligible, prescription sent to patient's preferred pharmacy or a partner pharmacy.
5. Follow-up virtual visits every 4–12 weeks for titration, safety monitoring, and continued prescription.

### Geographic distribution of specialists in 2026

| US Region | Obesity medicine specialists (ABOM) | Endocrinologists | Typical appointment wait |
|---|---|---|---|
| Northeast | ~1,700 | Dense | 3–8 weeks |
| Southeast | ~1,500 | Medium | 4–10 weeks |
| Midwest | ~1,400 | Medium | 4–12 weeks |
| Southwest (TX, OK, NM, AZ) | ~1,000 | Medium | 5–12 weeks |
| Mountain & Plains | ~500 | Lower | 6–16 weeks |
| West Coast (CA, OR, WA) | ~1,100 | Dense | 3–10 weeks |

Rural counties often have no ABOM specialists; telehealth is the primary access path in these areas.

### Pharmacy access

Brand GLP-1 medications are dispensed at:
- Retail chain pharmacies (CVS, Walgreens, Walmart, Rite Aid, Kroger, Costco, Publix).
- Mail-order / specialty pharmacies (Express Scripts, OptumRx, CVS Caremark, Accredo).
- Manufacturer direct programs (LillyDirect for Zepbound; Novo Nordisk savings programs for Wegovy/Ozempic).

Compounded GLP-1 medications (when legally available) are dispensed only by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.

## Alternatives to GLP-1 Therapy

Patients who are ineligible, cannot afford, or wish to explore alternatives have several evidence-based options in 2026.

### Older / non-incretin weight management medications

- **Phentermine** (Adipex-P, Lomaira): sympathomimetic appetite suppressant, short-term use. Typical weight loss 3–6%. Inexpensive ($15–40/month). Controlled substance Schedule IV.
- **Phentermine-topiramate** (Qsymia): combination. Weight loss 8–11%. Teratogenic — contraception required.
- **Naltrexone-bupropion** (Contrave): dual-mechanism. Weight loss 5–8%.
- **Orlistat** (Xenical prescription, Alli OTC): lipase inhibitor. Weight loss 3–5%. GI side effects limit use.
- **Setmelanotide** (Imcivree): rare genetic obesity syndromes only (POMC, LEPR, PCSK1 deficiency).

### Surgical options

For patients with BMI ≥ 35 (or ≥ 30 with comorbidities):

- **Sleeve gastrectomy**: removes ~80% of stomach. 60–70% excess weight loss. Most common bariatric procedure.
- **Roux-en-Y gastric bypass**: reroutes digestive anatomy. 70–80% excess weight loss, greatest long-term durability.
- **Adjustable gastric banding**: declining in popularity.
- **Endoscopic sleeve gastroplasty (ESG)**: non-surgical, suture-based. 15–20% weight loss.

### Lifestyle-only approaches

Comprehensive lifestyle intervention produces ~5–10% weight loss in structured programs. Evidence-based programs include the Diabetes Prevention Program (DPP, CDC-recognized), Mediterranean diet, and medically supervised very-low-calorie diets.

## Injection Logistics and Daily Management

### Timing and day of injection (weekly injectables)

- **Schedule**: once weekly, same day each week.
- **Time of day**: any time, with or without food.
- **Changing injection day**: the scheduled day may be changed if at least 3 days (72 hours) have elapsed since the previous injection.

### Injection technique and sites

- **Route**: subcutaneous (under the skin, not muscle).
- **Approved sites**: abdomen (at least 2 inches from umbilicus), thigh (front), upper arm.
- **Rotation**: rotate sites and spots within each site to prevent lipohypertrophy.
- **Pen**: single-dose pre-filled pen with auto-injector mechanism.

### Storage

- **Unopened pens**: refrigerator (36°F to 46°F / 2°C to 8°C) until expiration.
- **After first use or removed from refrigeration**: room temperature (up to 86°F / 30°C) for up to **21 days** (Ozempic, Wegovy, Mounjaro, Zepbound) or **28 days** (some formulations — check package insert).
- **Do not freeze**.
- **Travel**: insulated case with ice pack; TSA allows in carry-on.

### Missed dose rules

- **Weekly injections, within 5 days of missed dose (tirzepatide) or 5 days (semaglutide)**: inject as soon as remembered, resume schedule.
- **Beyond the window**: skip missed dose, resume schedule on next regular day.
- **Never double-dose**.

### Disposal

- Used pens: FDA-cleared sharps disposal container.
- Many pharmacies offer free sharps return programs.

## Special Populations

### Older adults (age ≥ 65)

No dose adjustment based on age alone. Monitor hydration and renal function due to susceptibility to GI side effects.

### Renal impairment

No dose adjustment for mild, moderate, or severe impairment. Monitor renal function during severe GI symptoms. Limited data in end-stage renal disease.

### Hepatic impairment

No dose adjustment for mild, moderate, or severe impairment. Limited data in severe disease.

### Pregnancy and lactation

Not recommended during pregnancy; insufficient human data, animal harm shown. Discontinuation at least 2 months before planned conception (5-day half-life → ~25 days for ≥ 95% clearance). Lactation: unknown excretion in human milk.

### Pediatric patients

- **Wegovy (semaglutide)** is FDA-approved for adolescents ≥ 12 years with BMI ≥ 95th percentile (approved December 2022).
- **Saxenda (liraglutide)** is FDA-approved for adolescents ≥ 12 years with BMI ≥ 95th percentile (approved December 2020).
- **Tirzepatide (Mounjaro, Zepbound)** is not yet FDA-approved for pediatric use; trials ongoing.

## Drug Interactions

### Oral medications (gastric emptying effect)

GLP-1 therapy delays gastric emptying, potentially altering absorption of oral medications:

- **Oral hormonal contraceptives**: reduced effectiveness during initiation and dose escalation. Additional non-oral contraception for 4 weeks after initiation and 4 weeks after each dose escalation.
- **Narrow therapeutic index oral medications** (warfarin, levothyroxine, digoxin): monitor more closely during titration.

### Insulin and sulfonylureas

Hypoglycemia risk increases substantially with combination therapy. Dose reduction typically required at GLP-1 initiation. Close glucose monitoring during titration.

### Other GLP-1 receptor agonists

**Concurrent use with another GLP-1 agonist is not recommended**. Overlapping mechanism without additive benefit, increased side effect risk.

### Alcohol

No specific contraindication. May exacerbate GI side effects and increase hypoglycemia risk with insulin/sulfonylureas. Pancreatitis history warrants minimized consumption.

## Safety Profile and Side Effects

Data from pivotal trials and FDA post-marketing surveillance.

### Most common adverse events (≥ 5% of patients)

- Nausea (up to 33% at highest dose, usually transient during titration).
- Diarrhea (up to 21%).
- Vomiting (up to 13%).
- Constipation (up to 11%).
- Dyspepsia.
- Abdominal pain.
- Fatigue.
- Injection site reactions.
- Hair loss (thinning, typically reversible).

### Serious adverse events (rare but labeled)

- Acute pancreatitis.
- Acute kidney injury secondary to severe dehydration from GI symptoms.
- Severe hypoglycemia (with insulin/sulfonylureas).
- Diabetic retinopathy complications (rapid glycemic improvement may worsen pre-existing retinopathy).
- Gallbladder disease (cholecystitis, cholelithiasis).
- Thyroid C-cell tumors (boxed warning based on animal studies; MTC/MEN 2 contraindication).

### Monitoring recommendations

- HbA1c for T2D patients, baseline and every 3 months until stable.
- Weight, BMI, blood pressure at each visit.
- Lipid panel annually.
- Monitor GI tolerance, adjust titration pace.
- Watch for pancreatitis, gallbladder disease, retinopathy changes.

## Tirzepatide vs Semaglutide: Head-to-Head Comparison

As of 2026, tirzepatide and semaglutide are the two leading GLP-1-based therapies in the United States. Key differences:

| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 mono-agonist |
| Brands (US) | Mounjaro, Zepbound | Ozempic (T2D), Wegovy (weight mgmt), Rybelsus (oral T2D) |
| Max weight loss (trials) | Up to 20.9% (SURMOUNT-1) | Up to 14.9% (STEP 1) |
| HbA1c reduction (T2D) | –2.0 to –2.4% | –1.5 to –1.8% |
| Route | Subcutaneous weekly | Subcutaneous weekly or oral daily |
| Weight mgmt approval | Nov 2023 (Zepbound) | Jun 2021 (Wegovy) |
| CV risk reduction approval | In development (SURPASS-CVOT, 2026–2027 readout) | March 2024 (Wegovy for CVD patients) |
| OSA approval | Dec 2024 (Zepbound) | Not approved |
| Common GI side effects | Similar profile | Similar profile |

Head-to-head SURMOUNT-5 (NEJM 2024): tirzepatide 15 mg produced 20.2% average weight loss vs semaglutide 2.4 mg producing 13.7% over 72 weeks in adults with obesity without diabetes.

## Clinical Evidence: Key Trial Programs

### SURMOUNT (tirzepatide for obesity and related indications, Eli Lilly)

- **SURMOUNT-1** (NEJM 2022): 72-week trial, up to 20.9% weight loss at 15 mg.
- **SURMOUNT-2** (The Lancet 2023): adults with T2D and obesity.
- **SURMOUNT-3** (Nature Medicine 2023): intensive lifestyle intervention + tirzepatide.
- **SURMOUNT-4** (JAMA 2024): weight maintenance after initial treatment.
- **SURMOUNT-5** (NEJM 2024): head-to-head vs semaglutide.
- **SURMOUNT-OSA** (NEJM 2024): obstructive sleep apnea in obese adults.
- **SURMOUNT-MMO** (ongoing): cardiovascular outcomes in obesity population.

### STEP (semaglutide for obesity, Novo Nordisk)

- **STEP-1** (NEJM 2021): 68-week trial, up to 14.9% weight loss at 2.4 mg.
- **STEP-2** (Lancet 2021): adults with T2D and obesity.
- **STEP-3** (JAMA 2021): intensive lifestyle intervention + semaglutide.
- **STEP-4** (JAMA 2021): weight maintenance after initial treatment.
- **STEP-5** (Nature Medicine 2022): two-year trial.
- **STEP-6** (Lancet Diabetes Endocrinol 2022): East Asian population.
- **STEP-8** (JAMA 2022): head-to-head vs liraglutide.
- **SELECT** (NEJM 2023): cardiovascular outcomes in overweight/obese adults with CVD — basis of Wegovy March 2024 CV approval.

### SUSTAIN / PIONEER (semaglutide for T2D, Novo Nordisk)

Series of trials establishing efficacy and CV benefit of Ozempic in T2D (SUSTAIN-6 NEJM 2016 foundational for CV effect).

### SURPASS (tirzepatide for T2D, Eli Lilly)

Series of trials establishing efficacy of Mounjaro in T2D. **SURPASS-CVOT**: ongoing cardiovascular outcomes trial, readout expected 2026–2027.

## The Complete GLP-1 Cost Landscape in 2026

### Retail cash prices without any insurance or discount (2026)

| Medication | Monthly retail cash (30-day) | Annual cash cost |
|---|---|---|
| Ozempic (semaglutide for T2D) | $900–$1,000 | $10,800–$12,000 |
| Wegovy (semaglutide for weight) | $1,250–$1,450 | $15,000–$17,400 |
| Rybelsus (oral semaglutide) | $900–$1,000 | $10,800–$12,000 |
| Mounjaro (tirzepatide for T2D) | $1,000–$1,200 | $12,000–$14,400 |
| Zepbound (tirzepatide for weight) | $1,060–$1,350 | $12,720–$16,200 |
| Saxenda (liraglutide for weight) | $1,300–$1,700 | $15,600–$20,400 |
| Trulicity (dulaglutide) | $880–$990 | $10,560–$11,880 |
| Victoza (liraglutide for T2D) | $550–$700 | $6,600–$8,400 |
| Generic liraglutide for T2D (since 2024) | Lower, varies | Varies |
| Bydureon BCise (exenatide) | $760–$900 | $9,120–$10,800 |

These are rough US retail averages. Prices at specific pharmacies vary; discount cards (GoodRx, SingleCare) can reduce by 10–30%.

### Manufacturer savings cards and copay programs

**Novo Nordisk (Ozempic, Wegovy, Rybelsus)**:
- **Ozempic Savings Card**: commercially insured patients may pay as little as $25/month for up to 24 months (lifetime maximum $500/month savings).
- **Wegovy Savings Card**: commercially insured patients may pay as little as $0/month if covered by insurance, $650/month if not covered.
- Eligibility excludes Medicare, Medicaid, TRICARE, VA beneficiaries.
- Verify current terms at [Novocare.com](https://www.novocare.com/).

**Eli Lilly (Mounjaro, Zepbound)**:
- **Mounjaro Savings Card**: commercially insured patients may pay as little as $25/month (3-month supply).
- **Zepbound Savings Card**: commercially insured patients may pay as little as $25 for covered, $650 for non-covered (30-day).
- **LillyDirect Self Pay Vials** (Zepbound): ~$349/month for 2.5 mg and 5 mg, $499 for 7.5 mg, $599 for 10 mg, $695 for 12.5/15 mg. Direct-to-consumer program bypassing insurance.
- Verify current terms at [Zepbound.lilly.com](https://zepbound.lilly.com/) and [Mounjaro.com](https://www.mounjaro.com/).

**Eligibility constraints**: All manufacturer programs exclude Medicare, Medicaid, TRICARE, VA beneficiaries. Self-pay vials (LillyDirect) accept anyone.

### Medicare Part D coverage (2026)

Medicare Part D covers GLP-1 medications based on FDA-approved indication, not on patient preference:

- **T2D medications (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus)**: generally covered. Formulary tier determines patient cost — typically $30–$150/month copay, with $2,000 out-of-pocket maximum per year under the Inflation Reduction Act (effective 2025).
- **Weight management alone (Wegovy, Zepbound for obesity)**: statutorily excluded under Social Security Act § 1860D-2(e)(2)(A).
- **Wegovy for cardiovascular risk reduction** (adults with CVD, BMI ≥ 27): Medicare Part D plans began covering Wegovy for this indication in 2024 following FDA expansion (March 2024). Copay varies.
- **Zepbound for obstructive sleep apnea** (adults with obesity): Part D plans began covering in 2025 following FDA expansion (December 2024). Copay varies.

**IRA $2,000 out-of-pocket cap (2025+)**: caps annual out-of-pocket Part D drug costs at $2,000 per year. Significantly benefits patients on expensive medications like GLP-1.

### Medicaid coverage (state-by-state)

- **T2D medications**: covered universally across all 50 states with standard utilization management.
- **Weight management medications (Wegovy, Zepbound, Saxenda)**: coverage varies by state. As of early 2026, approximately 15 states cover them for chronic obesity:
  - California, Pennsylvania, New York, Massachusetts, Virginia, Illinois, Michigan, North Carolina, Minnesota, Delaware, Rhode Island, New Hampshire, Vermont, Oregon, Washington.
- **CV / OSA indications**: generally follows Medicare pattern once approved.

Verify current coverage with your state Medicaid agency.

### Private commercial insurance

- **T2D**: typically covered with prior authorization, step therapy, and tier placement determining copay ($20–$150/month).
- **Weight management**: approximately 30–50% of large employer plans offered Wegovy/Zepbound coverage in 2025, increasing in 2026. Step therapy common (lifestyle trial, older obesity meds first), BMI thresholds often elevated above FDA label (≥ 35 or 40), quantity limits common.
- **CV (Wegovy)**: most plans covering Wegovy for weight management also cover for CVD indication.
- **OSA (Zepbound)**: coverage expanding rapidly in 2025–2026.

Self-insured employer plans (ERISA) set their own coverage rules. Check with your HR or benefits portal.

### Patient assistance foundations

For uninsured or underinsured patients who meet income eligibility:

- **NeedyMeds** ([needymeds.org](https://www.needymeds.org/)): aggregates patient assistance programs across manufacturers.
- **RxAssist** ([rxassist.org](https://www.rxassist.org/)): comprehensive PAP directory.
- **Partnership for Prescription Assistance** ([pparx.org](https://www.pparx.org/)): umbrella program for multiple manufacturers.
- **PAN Foundation** ([panfoundation.org](https://www.panfoundation.org/)): covers copays and deductibles for specific disease funds (diabetes, cardiovascular).

Manufacturer-specific programs:

- **Lilly Cares Foundation**: assistance with Mounjaro, Zepbound for qualifying patients.
- **Novo Nordisk Patient Assistance Program**: assistance with Ozempic, Wegovy, Rybelsus for qualifying uninsured patients.

Eligibility typically requires income under 400–500% of federal poverty level and uninsured or Medicare Part D status (for some programs).

### Cost-reduction strategies for uninsured or underinsured patients

**Strategy 1 — Manufacturer savings card** (if commercially insured): can reduce copay to $25/month.

**Strategy 2 — LillyDirect Self Pay Vials** (for Zepbound): $349–$695/month vials, no insurance required, no income restrictions.

**Strategy 3 — Mark Cuban Cost Plus Drugs** ([costplusdrugs.com](https://costplusdrugs.com/)): direct-purchase pharmacy for select medications. Currently limited GLP-1 options; check for current availability.

**Strategy 4 — GoodRx, SingleCare, RxSaver**: discount cards that can reduce cash price by 10–30% at participating pharmacies.

**Strategy 5 — Federally Qualified Health Centers (FQHCs)**: sliding-fee-scale care plus 340B drug pricing program may significantly reduce medication costs for qualifying patients. Directory: [HRSA Find a Health Center](https://findahealthcenter.hrsa.gov/).

**Strategy 6 — Employer weight management benefit**: check whether your employer offers a dedicated weight management benefit (Omada, Virta, Noom Med, Hims, Mochi, etc.) that may include subsidized GLP-1 access.

**Strategy 7 — HSA/FSA**: Health Savings Account and Flexible Spending Account funds can be used for GLP-1 medications (qualifying medical expense), reducing effective cost through pre-tax spending.

**Strategy 8 — Patient assistance foundations**: for patients meeting income criteria, manufacturer and third-party foundations may cover copays entirely.

**Strategy 9 — Generic alternatives**: generic liraglutide for T2D (approved June 2024) offers lower-cost GLP-1 option when clinically appropriate.

**Strategy 10 — Tax deduction**: medical expenses exceeding 7.5% of AGI are tax-deductible (itemized). High-cost GLP-1 may contribute to reaching that threshold.

### Annual cost scenarios

**Scenario 1 — Commercially insured with Wegovy coverage + savings card**:
- Insurance copay: ~$50/month.
- Savings card reduction: to $25/month.
- Annual cost: ~$300.

**Scenario 2 — Uninsured using LillyDirect Zepbound vials at 5 mg**:
- Monthly: $349.
- Annual: $4,188.

**Scenario 3 — Medicare Part D with Wegovy CV indication**:
- Plan premium: varies.
- Deductible and copay: variable.
- IRA $2,000 OOP cap: annual cost capped at ~$2,000 plus premium.

**Scenario 4 — Uninsured retail Mounjaro**:
- Monthly: $1,000–$1,200.
- Annual: $12,000–$14,400.

**Scenario 5 — Medicaid (eligible state) for Wegovy**:
- Patient cost: ~$0–$4/month copay.
- Annual: ~$0–$50.

### Medication cost beyond the prescription

- **Pharmacist dispensing fee**: typically included in retail price.
- **Delivery fees**: mail-order shipping usually free; same-day delivery $5–$15.
- **Consultation fees**: telehealth $50–$250 per visit; in-person copay variable.
- **Lab costs**: HbA1c, metabolic panel $50–$150 every 3–6 months.
- **Needles and sharps container**: usually included with pen (integrated auto-injector); separate disposal container $5–$20/year.

Total true cost of ownership for weight management GLP-1: $4,000–$18,000+ per year depending on insurance and cost-reduction strategies.

## Frequently Asked Questions

**What are GLP-1 medications used for?**
GLP-1 receptor agonists are FDA-approved for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus), chronic weight management in adults with obesity or overweight with comorbidity (Wegovy, Zepbound, Saxenda), cardiovascular risk reduction in overweight/obese adults with CVD (Wegovy, approved March 2024), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, approved December 2024).

**How much do GLP-1 medications cost without insurance in 2026?**
Typical retail cash price ranges from $900 to $1,700 per month for brand medications. Ozempic and Mounjaro: $900–$1,200. Wegovy and Zepbound: $1,060–$1,450. Saxenda: $1,300–$1,700. Eli Lilly's LillyDirect program offers Zepbound self-pay vials at ~$349–$695 for select doses. Compounded GLP-1 pricing varies; availability is restricted in 2026 post-FDA shortage resolution.

**Are GLP-1 medications covered by Medicare?**
Coverage depends on indication. T2D: generally covered under Part D (Ozempic, Mounjaro, Trulicity). Weight management alone: statutorily excluded under SSA § 1860D-2(e)(2)(A). Cardiovascular risk reduction (Wegovy, March 2024) and obstructive sleep apnea (Zepbound, December 2024): increasingly covered by Part D plans as of 2025–2026.

**Does private insurance cover GLP-1 medications for weight loss?**
Highly variable. Approximately 30–50% of large employer plans offered Wegovy or Zepbound coverage in 2025, with step therapy, BMI thresholds, and prior authorization. Coverage is expanding as obesity is increasingly recognized as a chronic disease.

**Is semaglutide or tirzepatide better?**
Tirzepatide (Zepbound) produced greater weight loss in head-to-head SURMOUNT-5 trial (NEJM 2024): 20.2% vs 13.7% for semaglutide over 72 weeks. Tirzepatide also achieves slightly greater HbA1c reduction in T2D. Semaglutide has a longer safety record, more indications with specific CV and obesity data, and approval for cardiovascular risk reduction. Choice depends on individual patient factors, insurance coverage, and prescriber preference.

**Is compounded semaglutide or tirzepatide still available in 2026?**
Availability is significantly restricted after the FDA resolved shortages (semaglutide October 2024, tirzepatide December 2024). Legal compounding is now typically limited to patients with a documented clinical need for a compounded formulation materially different from the FDA-approved commercial product. Verify current status at the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/).

**How much weight can I lose on GLP-1 medications?**
Trial averages: Wegovy (semaglutide) 14.9% at highest dose over 68 weeks (STEP-1); Zepbound (tirzepatide) 20.9% at highest dose over 72 weeks (SURMOUNT-1); Saxenda (liraglutide) 5–8%. Individual results vary substantially based on dose, duration, adherence, lifestyle, baseline weight, and individual biology.

**Who should not take GLP-1 medications?**
People with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome, known hypersensitivity, active severe gastroparesis, or during pregnancy. History of pancreatitis, gallbladder disease, or proliferative diabetic retinopathy requires careful risk-benefit assessment.

**What are the side effects of GLP-1 medications?**
Most common: nausea (up to 33%), diarrhea (up to 21%), vomiting (up to 13%), constipation, abdominal pain. Most GI symptoms emerge during titration and improve over time. Serious but rare: pancreatitis, acute kidney injury, severe hypoglycemia (with insulin/sulfonylureas), gallbladder disease, thyroid C-cell tumors (boxed warning).

**How do I get a prescription for GLP-1 medications?**
Valid prescription from a US-licensed provider required. Pathways: primary care physicians, endocrinologists, obesity medicine specialists (ABOM-certified), cardiologists, or licensed telehealth providers operating in all 50 states.

**How do I find a GLP-1 provider in the United States?**
Three pathways: (1) in-person providers — PCP, endocrinologist, ABOM specialist (directory at [abom.org](https://www.abom.org/)); (2) hospital-based weight management or bariatric programs; (3) telehealth platforms with US-licensed clinicians in all 50 states. Telehealth is the fastest pathway (days to 1 week); specialist appointments take 3–16 weeks.

**Is GLP-1 therapy available through telehealth in all 50 US states?**
Yes. GLP-1 medications are not controlled substances, simplifying telehealth prescribing. Licensed platforms operate across all 50 states through networks of US-licensed MDs, DOs, NPs, and PAs. State licensure compliance required.

**How quickly will I start losing weight?**
Most patients notice weight loss within the first 4–8 weeks. Significant clinical weight loss emerges after 12–24 weeks, continues over the first year, plateaus thereafter. Continued therapy is required for maintenance; discontinuation generally leads to partial or full regain.

**Can I take GLP-1 medications if I have type 1 diabetes?**
GLP-1 medications are not FDA-approved for type 1 diabetes. Off-label use outside research is not recommended.

**Can I stop GLP-1 therapy once I reach my goal weight?**
Evidence from STEP-4, SURMOUNT-4, and similar maintenance trials shows substantial weight regain after discontinuation (often within 12–18 months). Obesity is increasingly understood as a chronic disease requiring ongoing management. Taper decisions should be made with the prescriber.

**Can I use GLP-1 medications during pregnancy?**
No. Not recommended during pregnancy due to animal studies showing fetal harm and insufficient human data. Contraception counseling is standard. Discontinuation at least 2 months before planned conception recommended.

**How do GLP-1 medications affect birth control pills?**
Delayed gastric emptying can reduce effectiveness of oral hormonal contraceptives during initiation and dose escalation. Use an additional non-oral contraceptive method for 4 weeks after starting and 4 weeks after each dose escalation.

**Is GLP-1 therapy safe long-term?**
Safety data extend to approximately 3–5 years from clinical trials, with ongoing surveillance. No long-term safety concerns beyond labeled warnings have been identified as of 2026. Wegovy's SELECT cardiovascular outcomes trial (NEJM 2023) and SURMOUNT-MMO (ongoing) are establishing extended safety profiles.

**Can I inject GLP-1 medications at home?**
Yes. All weekly injectable GLP-1 medications are self-administered via pre-filled pen (subcutaneous injection). Daily injections (Saxenda) are also self-administered. Patient education on technique, rotation, and storage is standard.

**Are GLP-1 medications approved for cardiovascular disease?**
Wegovy (semaglutide) is FDA-approved for cardiovascular risk reduction in overweight/obese adults with established CVD (March 2024), based on SELECT trial results. This led to Medicare Part D coverage for CVD patients. Tirzepatide's cardiovascular outcomes trials (SURPASS-CVOT, SURMOUNT-MMO) are ongoing with readouts expected 2026–2027.

**Can I use GLP-1 medications for obstructive sleep apnea?**
Zepbound (tirzepatide) received FDA approval in December 2024 for moderate-to-severe OSA in adults with obesity. This indication expanded insurance coverage for qualifying patients. Other GLP-1 medications are not specifically FDA-approved for OSA.

**What's the difference between Ozempic, Wegovy, and Rybelsus?**
All three contain semaglutide. Ozempic is FDA-approved for T2D (weekly injection). Wegovy is FDA-approved for chronic weight management and CV risk reduction (weekly injection, higher max dose). Rybelsus is FDA-approved for T2D only (daily oral tablet). Insurance coverage rules differ significantly.

**What's the difference between Mounjaro and Zepbound?**
Both contain tirzepatide. Mounjaro is FDA-approved for T2D; Zepbound is FDA-approved for chronic weight management and OSA. Pens are technically similar; labeling, patient education, insurance rules, and pricing differ.

**Are Wegovy and Zepbound the same?**
No. Wegovy contains semaglutide (GLP-1 mono-agonist, Novo Nordisk). Zepbound contains tirzepatide (dual GIP/GLP-1 agonist, Eli Lilly). Both are FDA-approved for chronic weight management with similar eligibility criteria but different mechanisms, slightly different efficacy and side effect profiles, and different manufacturers.

**Do I need to diet while taking GLP-1 medications?**
The FDA label specifies use "as an adjunct to a reduced-calorie diet and increased physical activity." Clinical trial results were obtained in the context of lifestyle counseling. Lifestyle change is not optional for optimal and durable results.

**How long do the effects last after discontinuation?**
Clinical effects diminish as medication clears (half-life ~5–7 days for weekly injectables). Weight loss maintenance requires continued therapy; most patients regain substantial weight within 12–18 months after discontinuation, per STEP-4, SURMOUNT-4, and similar studies.

**Is GLP-1 therapy available without a prescription?**
No. All GLP-1 medications are prescription-only in the US. Purchasing from sources not requiring a prescription is illegal, unsafe, and often involves counterfeit or adulterated products.

**Can I drink alcohol while taking GLP-1 medications?**
No specific contraindication, but alcohol may exacerbate GI side effects, increase hypoglycemia risk (with insulin/sulfonylureas), and complicate pancreatitis risk. Moderation advised.

**What if I miss a dose?**
For weekly injectables, if within ~4–5 days of the scheduled dose, inject as soon as remembered. Beyond that window, skip and resume normal schedule. Never double-dose. For daily medications (Rybelsus, Saxenda), skip the missed dose entirely if it is almost time for the next.

**Can GLP-1 medications be combined with other weight loss medications?**
Not typically. Combining two GLP-1 agonists is not recommended. Combination with phentermine, bupropion-naltrexone, or metformin may be considered by specialists in specific cases but is off-label.

**What's the best alternative if I cannot access GLP-1?**
Depends on goals and eligibility. For T2D: non-GLP-1 options (metformin, SGLT2 inhibitors, insulin). For weight loss without GLP-1 access: phentermine (~$15–40/month), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave). For BMI ≥ 35 with comorbidities: bariatric surgery (sleeve gastrectomy, gastric bypass).

**How do GLP-1 medications compare to bariatric surgery?**
GLP-1 therapy (up to 20–22% weight loss) approaches sleeve gastrectomy efficacy (60–70% excess weight loss ≈ 25–30% total body weight) but is fully reversible. Surgery is more durable long-term but invasive, with 6–12 month insurance-mandated preparation. Combination approaches (surgery + GLP-1) are increasingly common.

**What time of day should I inject GLP-1 medications?**
Any time, with or without food. No pharmacologic reason to inject at a specific hour. Consistency helps — select a weekly day and time, stick to it.

**How should I store GLP-1 pens?**
Unopened: refrigerate (36°F–46°F). Opened or at room temperature: up to 21 days (varies by brand — check package insert) up to 86°F. Do not freeze. Travel: insulated case with cold pack.

**Is GLP-1 therapy safe for people over 65?**
Yes, with monitoring. No dose adjustment based on age. Older adults may be more sensitive to GI side effects; more frequent follow-up standard. Polypharmacy interactions with insulin and sulfonylureas common and require monitoring.

**Is GLP-1 therapy safe for people with kidney disease?**
Yes, with caution. No dose adjustment for mild to severe impairment. Severe GI side effects can precipitate acute kidney injury via dehydration. Limited data in end-stage renal disease.

**Can I take GLP-1 medications together with Ozempic or Wegovy?**
No. Concurrent use of two GLP-1 receptor agonists is not recommended. Mechanisms overlap without additive benefit; side effect risk increases. Transitioning between them requires prescriber guidance.

**Do GLP-1 medications affect other prescription medications?**
Yes. Delayed gastric emptying can alter absorption of oral medications (warfarin, levothyroxine, digoxin, hormonal contraceptives). Insulin and sulfonylureas require dose reduction due to hypoglycemia risk. Always inform prescribers of all medications.

**What is the real cost of GLP-1 medications without insurance in 2026?**
Retail cash prices: Ozempic and Mounjaro $900–$1,200/month; Wegovy and Zepbound $1,060–$1,450/month; Saxenda $1,300–$1,700/month. LillyDirect Self Pay Vials (Zepbound): $349–$695/month for specific doses. These are the highest out-of-pocket scenarios before any cost-reduction strategy.

**How can I reduce the cost of GLP-1 medications?**
Ten strategies: (1) manufacturer savings cards (commercially insured), (2) LillyDirect Self Pay Vials for Zepbound, (3) Mark Cuban Cost Plus Drugs for select meds, (4) GoodRx/SingleCare discount cards, (5) FQHC/340B pricing, (6) employer weight management benefits, (7) HSA/FSA funds, (8) patient assistance foundations (NeedyMeds, PAN), (9) generic liraglutide for T2D, (10) medical expense tax deduction.

**What is the LillyDirect Self Pay Vials program for Zepbound?**
A direct-to-consumer program from Eli Lilly where eligible patients purchase Zepbound vials (not pens) at reduced cash prices without insurance: ~$349/month for 2.5 mg and 5 mg, $499/month for 7.5 mg, $599/month for 10 mg, $695/month for 12.5 and 15 mg. No income restrictions; no insurance required.

**Does Medicare cover GLP-1 medications in 2026?**
Yes for FDA-approved indications other than weight loss alone. Mounjaro and Ozempic for T2D: covered. Wegovy for cardiovascular risk reduction (March 2024 FDA approval): covered for eligible patients. Zepbound for OSA (December 2024): covered for eligible patients. Weight management alone: statutorily excluded. The Inflation Reduction Act caps annual Part D out-of-pocket at $2,000 (effective 2025).

**What's the Inflation Reduction Act $2,000 cap and how does it help GLP-1 patients?**
The Inflation Reduction Act caps annual Medicare Part D out-of-pocket drug spending at $2,000 per year (effective 2025). For Part D beneficiaries on GLP-1 medications (for covered indications like T2D, CV, OSA), this cap significantly limits total annual cost exposure, regardless of list price.

**Can I use my HSA or FSA for GLP-1 medications?**
Yes. GLP-1 medications prescribed for an FDA-approved indication are qualified medical expenses. HSA/FSA funds (pre-tax) can be used to cover costs, effectively reducing the after-tax cost by 25–40% depending on your tax bracket.

**Does Medicaid cover GLP-1 for weight loss in 2026?**
Varies by state. All 50 states cover GLP-1 for T2D. Approximately 15 states cover Wegovy, Zepbound, or Saxenda for chronic obesity: California, Pennsylvania, New York, Massachusetts, Virginia, Illinois, Michigan, North Carolina, Minnesota, Delaware, Rhode Island, New Hampshire, Vermont, Oregon, Washington. Contact your state Medicaid agency for current coverage.

**Are GoodRx and Mark Cuban Cost Plus Drugs useful for GLP-1?**
GoodRx can reduce cash prices 10–30% at participating pharmacies for most GLP-1 medications. Mark Cuban Cost Plus Drugs offers direct-pricing for select medications but has had limited GLP-1 availability; check [costplusdrugs.com](https://costplusdrugs.com/) for current offerings.

**What are patient assistance foundations and do they cover GLP-1?**
Non-profit foundations (PAN Foundation, NeedyMeds, Partnership for Prescription Assistance) provide financial assistance for patients meeting income eligibility. Manufacturer-specific programs (Lilly Cares Foundation, Novo Nordisk Patient Assistance) help qualifying uninsured patients. Eligibility typically requires income under 400–500% of federal poverty level.

**Why do manufacturer savings cards exclude Medicare and Medicaid beneficiaries?**
Federal law prohibits using manufacturer savings cards in combination with federal healthcare programs (Anti-Kickback Statute). Medicare, Medicaid, TRICARE, VA, and Indian Health Service beneficiaries are excluded. This is a statutory constraint, not a manufacturer policy choice.

**Can my employer help cover GLP-1 costs?**
Increasingly yes. Many employers offer dedicated weight management benefits through third-party platforms (Omada, Virta, Noom Med, Hims Weight Loss, Mochi) that subsidize GLP-1 medication costs. Check with your HR or benefits portal.

**Is compounded GLP-1 significantly cheaper than brand?**
Historically yes (often $200–$500/month vs $1,000+ brand). In 2026, legal compounding availability is significantly restricted after FDA shortage resolution (October and December 2024). The price differential still exists for legally compounded prescriptions but access has narrowed.

**What is the total annual cost of long-term GLP-1 therapy?**
Depends heavily on pathway. Best case (Medicaid eligible + covered state): ~$50/year. Commercial insurance + savings card: $300–$1,200/year. Medicare Part D covered indication + IRA cap: up to $2,000/year for Rx plus premium. LillyDirect Self Pay: ~$4,200–$8,400/year. Uninsured retail: $10,500–$17,400/year.

## Glossary

- **ABOM**: American Board of Obesity Medicine, the US certification body for obesity medicine specialists.
- **503A pharmacy**: state-licensed compounding pharmacy for individual prescriptions, under Section 503A of the Federal Food, Drug, and Cosmetic Act.
- **503B outsourcing facility**: FDA-registered compounding facility for larger quantities, under Section 503B, subject to cGMP.
- **BMI (Body Mass Index)**: weight (kg) / height² (m²).
- **Compounded medication**: pharmacy-prepared, not FDA-approved, not reviewed by the FDA.
- **CVD (Cardiovascular disease)**: conditions affecting the heart and blood vessels.
- **Dual agonist**: medication that activates two distinct receptors. Tirzepatide is a GIP/GLP-1 dual agonist.
- **FDA**: US Food and Drug Administration.
- **GIP**: glucose-dependent insulinotropic polypeptide.
- **GLP-1**: glucagon-like peptide-1.
- **HbA1c**: glycated hemoglobin, a 3-month blood glucose average.
- **Incretin**: gut hormone (GIP, GLP-1) amplifying insulin secretion in response to oral glucose.
- **Medicare Part D**: Medicare prescription drug coverage.
- **Medicaid**: joint federal-state health coverage program for eligible low-income individuals.
- **Mounjaro**: Eli Lilly brand name for tirzepatide for T2D (FDA 2022).
- **Ozempic / Wegovy / Rybelsus**: Novo Nordisk brand names for semaglutide (T2D / weight mgmt / oral T2D).
- **OSA**: obstructive sleep apnea.
- **Prior authorization (PA)**: insurance requirement for prescriber documentation before coverage.
- **Step therapy**: insurance requirement to try less expensive alternatives first.
- **STEP**: Novo Nordisk's clinical trial program for semaglutide in weight management.
- **SURMOUNT**: Eli Lilly's clinical trial program for tirzepatide in weight management.
- **SURPASS**: Eli Lilly's clinical trial program for tirzepatide in T2D.
- **Titration**: gradual dose escalation to improve tolerability.
- **Zepbound**: Eli Lilly brand name for tirzepatide for weight management (FDA 2023) and OSA (FDA 2024).

## Official Sources 2026

All data in this document are drawn from or cross-referenced against the following primary US sources:

- [US Food and Drug Administration (FDA)](https://www.fda.gov/drugs/drug-approvals-and-databases) — FDA approval histories and label information.
- [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/) — current shortage status for semaglutide and tirzepatide.
- [FDA — Human Drug Compounding](https://www.fda.gov/drugs/human-drug-compounding) — regulatory framework for 503A and 503B compounding.
- [Centers for Medicare & Medicaid Services (CMS)](https://www.cms.gov/) — Medicare and Medicaid coverage policy.
- [Medicare.gov — Drug Coverage Search](https://www.medicare.gov/plan-compare/) — plan-specific formulary lookup.
- [DailyMed (NIH / NLM)](https://dailymed.nlm.nih.gov/) — official FDA package inserts.
- [ClinicalTrials.gov](https://clinicaltrials.gov/) — registry of SURMOUNT, SURPASS, STEP, SELECT, and other trials.
- [The New England Journal of Medicine](https://www.nejm.org/) — primary publication venue for SURMOUNT, STEP, SELECT.
- [JAMA — The Journal of the American Medical Association](https://jamanetwork.com/) — publication venue for STEP-3, STEP-4, SURMOUNT-4.
- [American Diabetes Association Standards of Care](https://diabetesjournals.org/care) — annually updated clinical guidelines.
- [American Heart Association — Scientific Statements](https://www.heart.org/) — cardiovascular clinical guidelines.
- [Obesity Medicine Association](https://obesitymedicine.org/) — clinical practice guidance.
- [American Board of Obesity Medicine (ABOM)](https://www.abom.org/) — certification directory.

## Additional Resources

- [Novo Nordisk — Ozempic patient site](https://www.ozempic.com/) — official T2D patient information.
- [Novo Nordisk — Wegovy patient site](https://www.wegovy.com/) — official weight management patient information.
- [Eli Lilly — Mounjaro patient site](https://www.mounjaro.com/) — official T2D patient information.
- [Eli Lilly — Zepbound patient site](https://zepbound.lilly.com/) — official weight management patient information, LillyDirect Self Pay.
- [GoodRx](https://www.goodrx.com/) — verified current retail pharmacy pricing.
- [Mark Cuban Cost Plus Drugs](https://costplusdrugs.com/) — direct-purchase pharmacy for select medications.
- [Medicare Plan Finder](https://www.medicare.gov/plan-compare/) — plan-by-plan drug coverage lookup.
- [NIH MedlinePlus](https://medlineplus.gov/) — consumer drug information.

## About This Page

costofglp1.com is a free information and matching platform that helps US-based patients navigate the full cost landscape of GLP-1 medications — manufacturer savings cards, Medicare and Medicaid coverage, private insurance, patient assistance foundations, LillyDirect Self Pay, and other cost-reduction strategies. The platform connects eligible patients with licensed telehealth providers and in-network specialists. The platform does not manufacture, prescribe, dispense, or sell medications and is not a healthcare provider.

**FDA Disclaimer**: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Compounded preparations referenced in this document are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. GLP-1 receptor agonists are prescription medications. Consult a licensed healthcare provider before initiating therapy. Individual results vary.

Last updated: April 2026.